Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Risk of COVID_19

NCT05398731 | Unknown

• 1 other identifier: ACEI,ARBS and risk of COVID_19
• Study Type: observational
• Target: 400
• Locations: 0 countries
• Sites: N/A

Brief Summary

1. 1.To determine the risk of COVID -19 in patients who use ACEI and ARBS
2. 2.To determine the Effect of ACEI and ARBS on COVID -19 infection .
3. 3.To determine the Severity of COVID -19 in patients who use ACEI and ARBS .

Conditions

COVID-19 Pneumonia

Outcome Measures

Primary Outcomes (1)

• determine the risk of COVID -19 in patients who use ACEI and ARBS

  determine the risk of COVID -19 in patients who use ACEI and ARBS

  from begining of Covid_19 pandemic up till now

Secondary Outcomes (1)

• determine the morbidity and Severity of COVID -19 in patients who use ACEI and ARBS

  from begining of Covid_19 pandemic up till now

Study Arms (4)

patients received ACEI

patient who use ACEI ( Duration, type of response, and the time period between the begining of and the emergence of symptoms of COVID-19)

Other: Covid_19

patients received ARBs

patient who use ARBs ( Duration, type of response, and the time period between the begining of and the emergence of symptoms of COVID-19)

Other: Covid_19

other antihypertensive drugs

patient who use other antihypertensive drugs(for example ca channel blockers and Beta blockers) ( Duration, type of response, and the time period between the begining of and the emergence of symptoms of COVID-19)

Other: Covid_19

non hypertensive group

Non hypertensive persons with matched age and sex

Other: Covid_19

Interventions

Covid_19 OTHER

Duration, type of response, and the time period between the begining of drug and the emergence of symptoms of COVID-19

Also known as: ARBs, ca channel blockers, Beta blockers

non hypertensive group; other antihypertensive drugs; patients received ACEI; patients received ARBs

Eligibility Criteria

• Age: 18 Years - 90 Years
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

questionnaire with 5 Domain: 1. Personal and demographic data, socioeconomic status. and other co comorbid diseases. 2. Included patients(groups) 3. Adherence of the patients to precautions against SARS-COV2. 4. SARS-CoV-2 infection: 5. Post COVID- 19 symptoms. 6. any investigation with the pt

You may qualify if:

• Age \>18 years old.
• patients who use ACEI
• patients who use ARBs
• patients who use other antihypertensive drugs(for example ca channel blockers or Beta blockers)
• Non hypertensive persons with matched age and sex

You may not qualify if:

• \< 18 years old.
• Pregnant or breast-feeding patients.
• Patients with autoimmune disease.
• Patients with multi organ failure, active cancer, renal insufficiency or chronic kidney disease.
• Patients received immunosuppressive drugs.
• Immune compromised patients.
• Patients with obstructive lung disease

Sponsors & Collaborators

• Assiut University: lead

Related Publications (6)

• Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol. 2015;1282:1-23. doi: 10.1007/978-1-4939-2438-7_1.

  PMID: 25720466 BACKGROUND

• Wang H, Yang P, Liu K, Guo F, Zhang Y, Zhang G, Jiang C. SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway. Cell Res. 2008 Feb;18(2):290-301. doi: 10.1038/cr.2008.15.

  PMID: 18227861 BACKGROUND

• Byrd, James Brian; Ram, C. Venkata S.; Lerma, Edgar V. 2019

  BACKGROUND

• Peng Zhang, Lihua Zhu, Jingjing Cai, Fang Lei, Juan-Juan Qin, Jing Xie, Ye-Mao Liu, Yan-Ci Zhao, Xuewei Huang, Lijin Lin, Meng Xia, Ming-Ming Chen, Xu Cheng, Xiao Zhang, Deliang Guo, Yuanyuan Peng, Yan-Xiao Ji, Jing Chen, Zhi-Gang She, Yibin Wang, Qingbo Xu, Renfu Tan, Haitao Wang, Jun Lin, Pengcheng Luo, Shouzhi Fu, Hongbin Cai, Ping Ye, Bing Xiao, Weiming Mao, Liming Liu, Youqin Yan, Mingyu Liu, Manhua Chen, Xiao-Jing Zhang, Xinghuan Wang, Rhian M. Touyz, Jiahong Xia, Bing-Hong Zhang, Xiaodong Huang, Yufeng Yuan, Rohit Loomba, Peter P. Liu, and Hongliang Li.April 2020

  BACKGROUND

• Bombardini T, Picano E. Angiotensin-Converting Enzyme 2 as the Molecular Bridge Between Epidemiologic and Clinical Features of COVID-19. Can J Cardiol. 2020 May;36(5):784.e1-784.e2. doi: 10.1016/j.cjca.2020.03.026. Epub 2020 Mar 29. No abstract available.

  PMID: 32299780 BACKGROUND

• Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, Hausvater A, Newman JD, Berger JS, Bangalore S, Katz SD, Fishman GI, Kunichoff D, Chen Y, Ogedegbe G, Hochman JS. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19. N Engl J Med. 2020 Jun 18;382(25):2441-2448. doi: 10.1056/NEJMoa2008975. Epub 2020 May 1.

  PMID: 32356628 BACKGROUND

MeSH Terms

Interventions

Adrenergic beta-Antagonists

Intervention Hierarchy (Ancestors)

Adrenergic Antagonists; Adrenergic Agents; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Pharmacologic Actions; Chemical Actions and Uses; Physiological Effects of Drugs

Study Officials

• Hanan M Adawy Nafeh, PhD

  Assiut University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Hanan M Adawy Nafeh, professor

CONTACT

01003053369; Hmnafeh@yahoo.com

Rasha M Shehata, Lecturer

CONTACT

01061607834; Rashahamed@aun.edu.eg

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Resident doctor

Study Record Dates

• First Submitted: May 19, 2022
• First Posted: June 1, 2022
• Study Start: June 1, 2022
• Primary Completion: March 1, 2023
• Study Completion: May 1, 2023
• Last Updated: June 7, 2022

Record last verified: 2022-05